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Summary   
 
This paper explores the potential therapeutic role of the naturally occurring sugar heparan 
sulfate for the augmentation of bone repair. Scaffolds comprising fibrin glue loaded with 
5 µg of embryonically-derived heparan sulfate were assessed, firstly as a release-
reservoir, and secondly as a scaffold to stimulate bone regeneration in a critical size rat 
cranial defect. We show heparan sulfate-loaded scaffolds have a uniform distribution of 
heparan sulfate, which was readily released with a typical burst phase, quickly followed 
by a prolonged delivery lasting several days. Importantly, the released heparan sulfate 
contributed to improved wound healing over a 3 month period as determined by µCT 
scanning, histology, histomorphometry and PCR for osteogenic markers. In all cases, 
only minimal healing was observed after 1 and 3 months in the absence of heparan 
sulfate.  In contrast, marked healing was observed by 3 months following heparan sulfate 
treatment, with nearly full closure of the defect site. PCR analysis showed significant 
increases in the gene expression of the osteogenic markers Runx2, alkaline phosphatase 
and osteopontin in the heparin sulfate group compared with controls. These results 
further emphasize the important role heparan sulfate plays in augmenting wound healing, 
and its successful delivery in a hydrogel provides a novel alternative to autologous bone 
graft and growth factor-based therapies. 
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Introduction 
 
The drive to develop bone regenerative therapies to circumvent delayed and non-union of 
bone fractures is an important therapeutic issue, especially considering the millions of 
fractures which occur annually, at least 10% of which are unable to heal by themselves. 
Several growth factors play key roles in the process of bone repair, and studies aimed at 
elucidating the factors affecting stem cell fate have recently demonstrated that the 
extracellular glycosaminoglycan sugar heparan sulfate (HS) plays a key role in the 
proliferation and differentiation of human bone marrow-derived mesenchymal stem cells 
(Cool & Nurcombe 2005). Osteogenic lineage fate decisions in general are known to be 
strongly influenced by several heparan-binding growth factors and it is widely accepted 
that fibroblast growth factors (FGFs) and their receptors (FGFRs) are essential to 
osteoblast differentiation and proliferation (Fakhry et al. 2005, Ornitz et al. 2001, Zhang 
et al. 2002). Much evidence has accumulated to show that FGF signaling, together with a 
large number of other growth and adhesive factors, is in fact controlled by HS (Jackson et 
al. 2006). 
 
Heparan sulfate is member of the glycosaminoglycan family of macromolecules. These 
are linear polysaccharides consisting of a repeating glucosamine/glucuronic acid 
disaccharide unit backbone attached to a protein core. HS has highly but variably sulfated 
sequences contained within its chains, organized into clusters that facilitate protein 
binding. These sulfated structural domain motifs are primarily responsible for the 
regulatory properties of HS (Guido et al. 1998). HS polysaccharides display versatilities 
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in conformation and orientation of functional groups which enable them to employ 
different modes of binding with protein complexes. These selective interactions with 
certain proteins results in regulation of protein activities (Cool & Nurcombe 2005). HS 
thus acts as a co-receptor, binding to heparin-binding growth factors such as FGF and 
BMP2, both protecting them from proteolytic degradation and promoting binding to their 
high affinity receptors (Turnbull et al 2001). HS has a low affinity yet high capacity for 
its ligands, drawing them onto the cell surface with their high-affinity cognate receptors, 
which then transduce the appropriate signal into the cells (Lyon et al. 1998). Moreover, 
HS binding is thought to be important in providing a matrix-bound pericellular reservoir 
of growth factors, promoting their long-term availability to cells (Saksela et al. 1989). 
The interaction of BMPs with their threonine-serine kinase BMP receptors is also thought 
to be mediated by HS (Irie et al. 2003, Takada et al. 2003, Coombe et al. 2005). And 
furthermore HS is thought to prevent diffusion of BMP2 in vivo, away from the regions 
where is it likely to be required (Depprich et al. 2005). 
 
Due to its ability to bind and potentiate bioactive molecules, there is growing evidence 
that the ECM-derived HS may prove to be a valuable adjunct for a variety of tissue 
engineering and wound-healing strategies that currently use growth factor treatments 
(Coombe et al. 2005). HS and its mimetics have been shown to improve bone 
regeneration when added exogenously in both long bone healing (Jackson et al. 2006) 
and cranial defect models (Blanquaert et al. 1995, Lafont et al. 2004). HS mimetics 
applied to a cranial defect model have shown an increase in new bone formation and 
neovascularization in the wound area over the first 5 days after injury. A single dose 
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application of HS to a rat femoral fracture at the time of injury has been demonstrated to 
increase callus size and bone volume after only 2 weeks (Jackson et al. 2006). Notably, 
these studies used single applications of HS in short-term delivery devices with 
promising results on the early stages of healing but triggered little difference in the later 
stages. Due to the temporal pattern of growth factor expression during bone repair, we 
have previously examined the prolonged localized delivery of HS over several days from 
polycaprolactone microcapsules (Luong-Van et al. 2007). 
 
Fibrin glue enjoys widespread clinical application as a wound sealant, a reservoir to 
deliver growth factors and as an aid in the placement and securement of biological 
implants (Vasita et al. 2006, Inman et al. 2003, Pandit et al. 2000, DeBlois et al. 1994). 
Several studies have shown that fibrin glue promotes the regrowth of peripheral nerves to 
levels comparable with standard microsurgery, making it a popular candidate for 
experimental nerve repair (Shireman et al. 1998). In the cellular environment, fibrin 
specifically binds to a variety of proteins, including fibronectin, albumin, FGF2, VEGF, 
and IL-1 (Fakhry et al. 2005). These properties make it an interesting drug and cell 
delivery system for various applications in tissue engineering (Vasita et al. 2006, Inman 
et al. 2003, Pandit et al. 2000, DeBlois et al. 1994, Rai et al. 2005). Previous studies have 
focused on capabilities with respect to tailoring the scaffold to generate release profiles of 
the growth factors over time. Here, we investigated the bone regenerative capabilities of a 
single dose of HS encapsulated within a fibrin glue scaffold when implanted into a 
critical sized rat calvarial defect model.  In vitro, we demonstrate the distribution and 
release of HS from fibrin glue scaffolds. In vivo, we utilized µCT scanning, histological 
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examination and RQ-PCR of osteogenic markers to examine the effects of HS on the 
process of bone regeneration.  
 
Materials and Methods 
 
Scaffold Fabrication 
Fibrin glue scaffolds were prepared using a commercial kit (TISSEEL kit; Baxter AG) as 
per the manufacturer’s instructions.  The mould for the cylindrical fibrin glue scaffold 
was a sterile, modified 1ml syringe (Figure 1A & B) that enabled easy application 
directly into the defect site once the scaffold had polymerized, so enhancing sterility by 
eliminating the need to handle any of the scaffolds (Figure 1C).  Fibrinogen (25 μl) was 
added to 25 μl of thrombin solution, producing a polymerized scaffold of approximately 
5 mm diameter and a thickness of 2 mm (Figure 1D). Two different concentrations of 
thrombin (Thrombin 4 and Thrombin 500) were investigated in vitro to optimize for the 
onset of in vivo experiments. The fibrin glue scaffolds created were used as a carrier-
matrix for the heparan sulfate (HS) delivery as well as to fill up the bone defect site. To 
incorporate HS into the scaffold, 5 μg (HS) was added to the thrombin component. This 
was thoroughly mixed and then pipetted into the sterile modified syringe body before 
adding the fibrinogen component. The ensuing polymerization of the glue and 
encapsulation of the HS took approximately 1 h. The scaffolds were then examined in 
vitro for a) HS release, to observe the release kinetics of HS from the fibrin glue; b) 
confocal microscopy, to observe the distribution of HS throughout the fibrin glue 
scaffold; and c) in vivo implantation and µCT evaluation of bone mineralization and 
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histological examination. For the purpose of this study, all in vitro experiments were 
undertaken using Heparin (Sigma) as a control substitute for HS. Heparin is structurally 
similar to HS, and is believed to distribute and release in the same way within a scaffold. 
It can be easily conjugated to the fluorescent label Alexa Fluor-488, enabling its 
distribution to be localised and viewed using confocal microscopy, and its release 
quantified using fluorescent plate reading. All in vivo work utilized HS.  
 
Confocal Microscopy 
Heparin was fluorescently conjugated with Alexa Fluor-488 (A488, Molecular probes) 
using a method adapted from Osmond et al. (2002), prior to incorporation into the 
scaffold. To visualize the distribution of heparin, scaffolds were viewed using confocal 
laser scanning microscopy (Zeiss LSM S10 meta inverted microscope). Three 
dimensional depth projections were constructed from 100 horizontal slices of step size 10 
m.   
 
Release Kinetics 
Fibrin glue scaffolds containing 5 ug Alexa Fluor-488-labelled heparin were placed into 1 
ml of pre-warmed phosphate buffered saline (PBS) and incubated at 37oC, protected from 
light, for a 7 day period. At each time point, 100 l of PBS was removed for sampling 
and replaced with fresh PBS. The heparin released was quantified from the fluorescence 
intensity of the release media at 485 nm by comparison with a standard Alexa Fluor-488-
heparin curve. The cumulative release was then graphed.  
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Surgery 
The in vivo study involved the creation of two 5 mm diameter defects in the parietal 
bone. 20 female Wistar rats (300-400 gm) were used with approval from the Institutional 
Animal Care and Use Committee (IACUC), Singapore. They were randomly divided into 
3 groups: (a) empty defects, (b) fibrin glue defects containing fibrin glue scaffold alone; 
and (c) fibrin glue defects containing fibrin glue scaffold encapsulated HS (5 g). 
 
Prior to surgery, the rats were given intra-peritoneal anesthesia of 75 mg/kg Ketamine & 
1 mg/kg Medetomidine, the heads were shaved and saline-soaked gauze applied across 
the eyes. Under aseptic technique, the skin over the calvaria was disinfected with 
Betadine™, the skin over the parietal bone dissected in the sagittal plane and the 
periosteum removed from the both sides of the parietal bone. As previously described, a 5 
mm diameter trephine was used to create two circular through-and-through, critical-sized 
bony defects 1 which were irrigated with saline to remove blood clots; hemostasis was 
achieved with gentle pressure. The fibrin glue scaffolds +/- HS were applied directly into 
the defect sites utilizing the novel syringe system. The skin was closed with 5-0 
absorbable coated vicryl sutures (polyglactin 910, Johnson and Johnson). The animals 
were then given reverse anesthetics (5 mg/ml of antisedan), antibiotics and temegesic 
pain killers. They were placed individually in cages with food and water, and observed 
postoperatively for adverse effects.  
 
Micro computed tomography (µCT) scanning  
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At 1 month and 3 months after surgery, the rats were anesthetized intra-peritoneally as 
previously described before undergoing µCT scanning to obtain a quantitative measure of 
the levels of regenerated bone (SKYSCAN-1076 in vivo micro computerized tomography 
scanner, Belgium). As previously described, imaging was performed with 68 mm scan 
width, an Al-1 mm filter, 35 µm pixel size, using an average of 4 sets of scan data per 
sample (Shao et al. 2006). All samples were scanned through a 180° rotation angle with a 
rotation step of 0.8° at 35 μm resolution. The data were volumetrically reconstructed 
using cone beam CT reconstruction software from SKYSCAN at 1968x1968 pixels. Files 
were then reconstructed for analysis by Mimics v 8.11 software (Materialize, Belgium) 
using in-built functions.  From the 3D image, a cylindrical region of interest (ROI) of 
defect size of 5 mm diameter was selected for analysis. This ROI corresponds to the 
original defect location. The degree of bone regeneration occurring within the defect was 
presented as a volume in mm3 of reconstructed data obtained in micro CT analysis. The 
threshold was adjusted empirically to visualize the defect site and the mineralization and 
was then kept constant for every sample (-284 to 1420 HUs for all reconstructions). 
Defect reconstruction was attained by subtracting the scanned mineralization data.  
 
Histology and histomorphometry 
Animals were sacrificed at 3 months in a CO2 chamber. After euthanasia, tissue was 
dissected from the calvarial bone and the defect site sectioned for histology. For 
processing, tissue was fixed in 10% neutral buffered formalin for 2 days and de-calcified 
in 12.5% EDTA (Sigma Aldrich) pH 7.0 for 3 weeks. The samples were then serially 
dehydrated in ethanol in a tissue processor (Shandon Citadel 1000, Thermo Scientific), 
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and paraffin embedded (Leica EG 1160). Sections (5 μm) were taken using a microtome 
(Leica RM 2135). The slides were deparaffinized with xylene and rehydrated with serial 
concentrations of ethanol, before being stained with haematoxylin and eosin (Sigma 
Aldrich, USA) and mounted with DPX mountant (Fluka Biochemica, USA). 
Immunohistological staining was also used employing mouse monoclonal antibodies 
against type I collagen (Sigma Aldrich, USA) at 1:500 dilution, osteopontin (Santa Cruz) 
1:50 dilution, and osteocalcin (Abcam, UK) at 1:150 dilution. Secondary antibodies were 
rat absorbed anti mouse IgG (Vector Labs, USA). The antigens were localized using an 
immunoperoxidase procedure according to the manufacturer’s guidelines 
(VECTASTAIN® ABC kit, Vector Labs, USA). The isotype mouse IgG1 antibody was 
used as a negative control (Caltag Laboratories). 
 
Histomorphometry was performed using Bioquant Osteo II software to quantify the 
percentage staining for collagen I, osteocalcin and osteopontin within the defect site. 
Briefly, a region of interest was manually drawn around the defect site. The entire defect 
site was first quantified (total area), and then the percentage of positive stain for each of 
the aforementioned proteins was quantified and expressed as a percentage of the entire 
defect site. This positive stain was obtained by manually thresholding the images and 
directing the software to pick up only the positive stains attributable to the protein of 
interest (attained through comparisons with negative controls). The thresholds were saved 
and applied to every slide within the data set, for each stain. 
 
RNA isolation and RQ-PCR 
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Following sacrifice of the animals, the defect sites were surgically collected and 
immediately frozen using liquid nitrogen. The extracted tissue was then ground to 
powder form with a mortar and pestle. Total RNA was extracted using Trizol reagent 
(Invitrogen Corp., USA) and subsequent clean up using an RNeasy Mini Kit (QIAGEN, 
Singapore) according to the manufacturer's instructions. The quality of the isolated RNA 
was assessed by gel electrophoresis and quantitated on a Genequant RNA/DNA 
Spectrophotometer (Amersham Biosciences, Piscataway, NJ, USA) and stored at -80°C 
until further use. For conversion to cDNA, 500 ng of total RNA was reverse-transcribed 
using random hexamers catalysed by Superscript III RT (Invitrogen Corp., USA). 
Following spectrophometric quantitation of the cDNA, expression levels of the target 
genes were determined using RQ-PCR.  Briefly, 120 ng of cDNA was amplified using the 
ABI Prism FAST 7500® sequence detection system (PerkinElmer Life Sciences, 
Wellesley, MA, USA) using the default cycle: 95C x 20 sec followed by 40 cycles of 
95C x 3 sec, 60C x 30 sec. Runx2, osteopontin and 18S primers and probes were 
designed using Primer Express software (v 2.1, PE Applied Biosystems, Foster City, CA, 
SA), and have been described elsewhere (Ng et al. 2007). Alkaline phosphatase primer 
and probes were purchased as an Assay-on-demand (PE Applied Biosystems, Foster City, 
CA, USA). The Runx2 and osteopontin LNA probes were re-designed to incorporate 
LNA bases and labeled with BHQ-1 (Proligo, Singapore). The ribosomal subunit gene 
18S (VIC/TAMRA) was used as the endogenous control. Data was analyzed using the 
ABI Sequence Detector software. Amplifications were performed three times in 
triplicate.  Target gene expression values were calculated relative to the endogenous 
control 18S expression levels using the (2(-DDCt)) calculation. 
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Statistical analysis 
A two-way ANOVA with differences considered significant at the 95% confidence 
interval, was used to determine significant differences between mineralization within the 
HS and non-HS treated scaffolds followed by the Bonferroni post-test. Standard error 
bars were included in all graphs and represent the 95% confidence interval. 
 
Results  
 
In vitro analysis of HS-loaded Fibrin glue scaffolds 
To examine the distribution of heparin through the fibrin scaffold and to assess its time-
release, a combination of confocal microscopy and fluorescent spectroscopy was 
performed. Confocal microscopy demonstrated a uniform distribution of heparin (HS 
substitute) throughout the fibrin scaffold. Sequential scans of 10 µm slices were taken 
and showed no significant change in heparin distribution between each slice throughout 
the whole body of the scaffold (data not shown). However, following several trials, the 
polymerization rate of Thrombin 500 was determined to be too rapid, prone to air bubbles 
and uneven encapsulation of the heparin component. 
 
When we compared the release kinetics of heparin from the scaffold, using both 
Thrombin 4 and Thrombin 500 components, similarities were observed. The release from 
both scaffolds followed the same pattern; a fast initial burst with over 50% release within 
the first 4 h, followed by a sustained release over the course of 4 days, at which time 
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100% of the heparin had been released (Figure 2). As a result only the Thrombin 4 dosed 
scaffolds were used for the in vitro analyses.  
 
In vivo analysis of HS-loaded fibrin glue scaffolds 
The effect of HS on augmenting in vivo bone healing was first assessed by µCT and 
histomorphometry. MicroCT scanning detected an increase in mineralization for those 
defect sites treated with HS at both 1 month and 3 months. Representative reconstructions 
of the defect sites at 1 month and 3 months for all treatments are presented in Figure 3. 
All treatments demonstrated significant increases from month 1 to 3 within their 
respective groups. At 3 months the HS-treated sites had full closure of the defect with 
mineralized bone. When quantiated using the MIMICs software, significantly higher 
mineralised bone was present in the HS treated sites at 3 months when compared with 
empty defect sites and fibrin glue alone defect sites (p<0.05). No significant differences 
were observed between the treatment groups after 1 month. 
 
We then examined the isolated and sectioned samples histologically using hematoxylin 
and eosin (H&E) staining and immunohistochemistry.  The fibrin glue alone defect sites 
appear to have residual bone chips present from surgery, possibly owing to incomplete 
drilling through the parietal bone, and  appear to be composed of newly formed bone with 
more intense and uniform staining, containing sparse non-contiguous islands within the 
defect area (Figure 4b). The empty defects appear to have only sparse fibrous connective 
tissue bridging between the bony fronts (Figure 4a). In the HS treated samples, newly 
formed, contiguous bone can be observed with and surrounding all edges of the defect 
site (Figure 4c). The osteogenic markers collagen type I, osteocalcin and osteopontin all 
 - 14 - 
gave demonstrably higher staining within the HS treated groups when compared with 
empty defects. Collagen I was lowly detectable and disordered in both the empty and 
fibrin glue defect sites (Figures 4d and 4e). In contrast, in the HS-treated samples, 
collagen I had a more organized and fibrillar appearance along the direction of the fibrous 
tissue, contiguous with the structured bone edges of the defect site (Figure 4f). 
Osteocalcin staining was very low in both the empty and fibrin defect sites, with signal 
detected predominantly in the bone edges of the defect site (Figure 4g and 4h). In the HS-
treated defect sites, osteocalcin staining was uniform throughout both the bone edges and 
the repaired defect site (Figure 4j). Osteopontin was very low in the empty defect 
samples (Figure 4j) but was present throughout the fibrin-treated defects (Figure 4k). The 
distribution of osteopontin throughout the HS-treated defects appeared to be mostly 
localised to the bone edges (Figure 4l). When we quantified the staining within the defect 
sites using Bioquant analyses, these observations were reinforced with HS-treated defects 
determined to have significantly higher levels of collagen type I, osteocalcin and 
osteopontin at 3 months (Figure 5). 
 
RQ-PCR analysis of treatment sites 
To further assess bone formation, we examined the osteogenic markers Runx2, alkaline 
phosphatase and osteopontin using RQ–PCR in the fibrin glue and HS treated samples.  
As expected, the fibrin glue alone samples demonstrated expression of all three 
osteogenic markers examined, confirming the presence of osteogenic-committed cells 
within the isolated defect sites. Significant upregulation of all markers was demonstrated 
in the HS-treated samples. Notably, Runx2 was upregulated 6-fold, alkaline phosphatase 
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3-fold and osteopontin 2-fold (data not shown). The comparison of the Runx2 and 
alkaline phosphatase data are presented in Figure 6.  
 
Discussion 
 
Bone is a dynamic and multifunctional organ capable of remodeling and self-
regeneration. However, in extreme cases of non-union or delayed fracture union, 
therapeutic intervention is often required. In conventional procedures, the transplantation 
of bone requires invasive procedures including skin and mucosal incisions and resection 
of the periosteum. The ability to implant a bioactive scaffold with osteoinductive 
properties within a critical sized defect is an attractive one, especially if the therapy 
negates the requirement to include live cells in the scaffold.  
 
It has been shown that the local or systemic application of a number of growth factors 
such as FGF2 and BMP2 (Fakhry et al. 2005, Blanquaert et al. 1995) can aid bone repair. 
Disadvantages of such applications include their rapid clearance rates and susceptibility 
to proteolytic degradation (Babensee et al. 2000). Additionally there is concern over their 
long-term safety and associated costs, particularly as large quantities are required. 
Heparan sulfate binds to a variety of soluble proteins involved in the control of cell 
phenotype, including heparin-binding growth factors. The HS mode of action is to 
concentrate growth factors close to cells, protect them from extracellular proteases, 
shepherd them to the cell surface and facilitate binding to their specific receptors (Zhang 
et al. 2002).  The complexes formed can be readily dissociated and mobilized in the event 
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of tissue damage, resulting in prolonged bioactivity at the site of damage (Coombe et al. 
2005). HS has been implicated in facilitating and stabilising the interaction of FGFs with 
their receptors. The more complicated interaction with BMPs have been demonstrated to 
include a stabilizing and storage role in the extracellular space (Ruppert et al. 1996), 
maintaining the growth factor spatially away from it’s receptor, thus limiting signaling 
potential (Takeda et al. 2003) and preventing diffusion from a site of injury (Depprich et 
al. 2005), however these interactions act in unison to modulate the activity and it has not 
yet been shown that HS interacts directly with the BMP2/receptor complex. Nontheless, a 
synergistic interaction seems apparent between HS and BMP2, although the exact 
mechanism driving this is still unknown. We and others, have previously demonstrated 
increased bone regeneration through addition of HS and HS-like molecules. Heparan-like 
mimetics (carboxymethy-lbezylamide-sulfonated dextrans) have been reported to induce 
the repair of rat skull defects (Lafont et al. 2004), and single doses of HS have been 
shown to augment fracture repair in a rat model (Jackson et al. 2006). 
 
Fibrin glue is a physiologically relevant matrix whose principle component, fibrin, has 
fundamental roles in the process of blood clotting and wound healing. It is also a 
potentially suitable biological vehicle for cell transplantation, as it has proven 
biocompatibility, biodegradability and binding capacity to cells (Mundlos et al. 1997). 
Fibrin stabilizing factor XIII, contained in fibrin glue, favours migration of 
undifferentiated mesenchymal cells on the highly cross linked structure of the glue and it 
enhances proliferation of these cells (Otto et al. 1997, Choi et al. 2005). The fibrin glue 
scaffolds in this study were comprised of a low concentration of thrombin (thrombin 4), 
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as the suitability and incorporation of the HS into the polymerizing glue proved difficult 
using higher concentrations (thrombin 500). Increasing the thrombin concentration has 
previously been demonstrated to affect fiber thickness, porosity and homogeneity of the 
fibrin (Pratap et al. 2003). Given the promising therapeutic potential of HS, this study 
sought to investigate the effects of HS on bone regeneration within a critical sized rat 
cranial defect using fibrin glue as a release reservoir.  
 
Initial in vitro studies demonstrated heparin (the control for HS) was released rapidly in 
the first 4 h from the fibrin glue scaffolds, with over 50% of the total heparin released in 
the first 4 h, followed by a sustained release (up to 100% over 4 days). When applied in 
vivo, this sharp burst may provide a large, initial stimulus for growth factor recruitment 
and concentration and thus an accelerated onset of bone regeneration. Although the HS is 
not physically attached to the scaffold, and probably diffuses away from the wound site 
fairly rapidly, it appears that the initial high presence (~5ug) of HS within the site of 
injury is sufficient enough to stimulate an enhanced regenerative response. Indeed, the 
local gradient of HS within the vicinity of the wound site may provide an environment 
which produces a corresponding gradient of growth factors, a known stimulator for 
migrating cells.  Such gradients may affect subsequent wound healing by guaranteeing a 
store of pre-activated growth factors immediately adjacent to the wound site, which in 
turn would act to stimulate the recruitment of more stem cells into the wound site. 
We next examined how to determine the best doses and release profiles required for 
optimal bone regeneration over a longer period in vivo. We utilised µCT scanning to 
determine bone mineralization within the defect sites and reinforced this with histological 
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and histomorphometrical examination of the defect sites and gene expression analyses of 
isolated tissue. 
 
MicroCT analysis showed significant bone regeneration within defects treated with HS 
compared to empty defects and fibrin glue alone, with full closure of sites observed after 
3 months. Histological analysis showed clear differences in tissue formation among the 
different treatment conditions. Sparse fibrous connective tissue was found to traverse the 
empty defects, compounded by the lowest levels of staining for collagen I, osteocalcin 
and osteopontin. In contrast, in the HS treated samples, newly formed bone was clearly 
observed surrounding all edges of the defect site, with contiguous bone within the defect 
site demonstrating intense and uniform staining for the osteogenic markers. Quantitative 
analysis reinforced the observed immunohistochemical data with significantly higher 
levels of collagen I, osteocalcin and osteopontin within the HS-treated defect sites. 
Additionally, using RQ-PCR, gene expression of key osteogenic markers was also 
demonstrated, with increased Runx2, alkaline phosphatase and osteopontin in the HS 
treated groups. It is of note that due to the amount of tissue available, the yield and 
quality of extracted RNA from the empty defect sites was significantly lower than the 
other treatment conditions. Runx2 is regarded as the key regulator of osteogenesis and 
has been shown to be essential for skeletal patterning during embryogenesis and the 
progression of osteoblast differentiation (Keller et al. 1985, Kasai et al. 1983, Marktl et 
al. 1974, Le Nihouannen et al. 2006, Ducy et al. 1999). Calvarial cells harvested from 
Runx2-deficient mice have increased rates of cell proliferation, DNA synthesis and G1/S 
phase markers; the reintroduction of Runx2 restores normal cell cycling, emphasizing the 
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importance of Runx2 for cell cycle regulation (Komori et al. 1997).  Reports have 
suggested the addition of HS can increase the expression of Runx2, alkaline phosphatase 
and osteopontin in preosteoblast cells, suggesting the potential for exogenous HS to shift 
cells from proliferative to differentiative phenotypes (Jackson et al 2006). These results 
are consistent with this hypothesis. 
 
The current study evaluated a previously verified dose of heparan sulfate encapsulated 
within a fibrin glue delivery system, for its ability to influence sustained bone repair 
within critical sized rat cranial defects. Our results suggest that by enhancing growth 
factor activity within the defect site, HS mediates increased bone repair reflected by 
increased mineralised bone and osteogenic marker expression. These data suggests the 
HS may have a significant therapeutic role in bone regeneration. 
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Figure Legends: 
Figure 1. Fibrin glue scaffold fabrication. Thrombin, fibrinogen and HS were mixed and 
polymerized in the barrel of a 1 ml modified syringe (A) and ejected after production (B). 
The sterile fibrin scaffold produced had dimensions of approximately 5 mm in diameter 
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and a thickness of 2 mm (D), which could then be easily implanted directly into the 5 mm 
defect sites (C). 
 
Figure 2. In vitro analysis of release kinetics of Alexa-468-heparin from fibrin scaffolds 
revealed a sharp initial burst of over 50% total heparin released in the first 4 h followed 
by a sustained release of up to 100% over 4 days. ▲= Thrombin 500 ●=Thrombin 4. 
 
Figure 3. Quantified µCT analysis of defect sites at 1 month and 3 months for empty 
defect sites, fibrin glue alone and HS treated sites. Representative CT images were 
analysed using MIMICs evaluation of the total volume of mineralized bone, in mm3, 
detected within the defect sites. * denotes a significant difference between HS treated 
sites and all other defect sites at 3 months. 
 
Figure 4. Representative photographs of tissue section analysis of haemotoxylin and 
eosin (a-c), and immunohistochemistical staining for type I collagen (d-f), osteocalcin, g-
i) and osteopontin (j-l) within each defect site after 3 months.  
 
Figure 5. Quantitation of staining as a percentage of total tissue formation after 3 months 
determined using Bioquant image analysis software. * denotes a significant difference 
between HS treated sites and all other sites. 
 
Figure 6. RQ-PCR analysis of osteogenic markers showing Runx2 and alkaline 
phosphatase expression comparing tissue from defect sites with fibrin glue alone and HS 
fibrin glue scaffolds at 3 months.  
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